Type 1 diabetes mellitus (T1D) is an autoimmune endocrine disorder in which islet cells are ablated by the immune system, rendering patients dependent upon the injection of exogenous insulin for their whole lives. The Edmonton protocol represents a milestone in clinical studies of islet transplantation; islets were infused through the portal vein and transplanted at the intrahepatic site1. However, two main obstacles-inadequate sources of donor islets and poor islet engraftment-prevent the wide success of the islet transplantation2. Usually, islets need to be collected from three cadaveric donors to reverse the hyperglycemic condition of one patient; this is due to the low yield of islet isolation procedures and the islet loss after transplantation. In particular, although the post-transplantation islets were bathed in oxygen-rich blood, the direct contact with blood often evoked the instant blood-mediated inflammatory reaction (IBMIR), which could cause the acute loss of the islets. In the long term, it is thought that the gradual loss of islets in patients accounted for the drop of diabetes reversal rates in the clinical groups, which could reach 90% in the first year and declined to 30% and 10% by 2 and 5 years post-transplantation, respectively3.
Islet transplantation at extrahepatic sites has been an attractive strategy to reduce the direct contact of islets with blood while confining the transplants to more definable locations compared to intrahepatic infusion. Studies have been carried out in the kidney capsule, eye, muscle, fat pads, and subcutaneous spaces over the past years, showing that islets at these sites are able to survive and function to restore normoglycemia4. In addition, the islets at these sites are retrievable, making it possible for biopsy or even for further replacement procedures. Extrahepatic sites therefore demonstrate great potential for clinical transplantation5.
Biomaterial-based scaffolds have been intensively investigated for cell transplantation and tissue engineering. Three-dimensional (3D) scaffolds usually contain porous structures and can serve as cellular templates to generate spatial structure/organization of cells or as reservoirs to provide the controlled release of bioactive cues. Scaffolds have also been fabricated from polymeric materials, such as poly(glycolide-L-lactide)6, poly(dimethylsiloxane)7, and thermoplastic poly(urethane)8, to transplant islets in the EFP. Compared to the direct transplantation of islets, the use of scaffolds was found to reduce islet loss by preventing the leakage of islets into the intraperitoneal cavity9,10, providing mechanical protection and modulating the local inflammatory reaction. The scaffolds thus may be developed to promote islet engraftment at the transplantation sites7.
In this study, we intend to demonstrate a paradigm of islet transplantation in the EFP, carried out in mice models using a DCS. Scaffolds derived from extracellular matrices have attracted great interest in recent years due to the superior biocompatibility and more natural porous structures compared to synthetic products. Here, we describe a robust isolation protocol to obtain pancreatic islets at high yields from C57BL/6J mice. DCSs processed from the bovine pericardium were then seeded with islets, and the grafts were transplanted to the EFP in syngeneic diabetic models. Normoglycemia in mice was achieved within 10 days and was maintained for up to 100 days, until the removal of the grafts.